1.Greenspon, AJ, Patel, JD, Lau, E, et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States, 1993–2008. J Am Coll Cardiol 2011;58:1001–1006.
2.Greenspon, AJ, Patel, JD, Lau, E, et al. Trends in permanent pacemaker implantation in the United States from 1993 to 2009: increasing complexity of patients and procedures. J Am Coll Cardiol 2012;60:1540–1545.
3.Mehrotra, P, Gupta, K, Strymish, J, et al. Implementation of infection prevention and antimicrobial stewardship in cardiac electrophysiology laboratories: results from the SHEA Research Network. Infect Control Hosp Epidemiol 2017;38:496–498.
4.de Oliveira, JC, Martinelli, M, Nishioka, SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:29–34.
5.Strymish, J, Welch, B, Peralta, A, et al. Implementation of a surgical site infection prevention bundle in the cardiac electrophysiology laboratory for management of a cluster of device infections. Open Forum Infect Dis 2016;3:S1.
6.Ali, S, Kanjwal, Y, Bruhl, SR, et al. A meta-analysis of antibacterial envelope use in prevention of cardiovascular implantable electronic device infection. Therapeut Adv Infect Dis 2017;4:75–82.
7.Ahsan, SY, Saberwal, B, Lambiase, PD, et al. A simple infection-control protocol to reduce serious cardiac device infections. Europace 2014;16:1482–1489.
8.Manolis, AS, Melita, H. Prevention of cardiac implantable electronic device infections: single operator technique with use of povidone-iodine, double gloving, meticulous aseptic/antiseptic measures and antibiotic prophylaxis. Pacing Clin Electrophysiol 2017;40:26–34.
9.Krahn, AD, Longtin, Y, Philippon, F, et al. Prevention of arrhythmia device infection trial: the PADIT trial. J Am Coll Cardiol 2018;72:3098–3109.
10.Polyzos, KA, Konstantelias, AA, Falagas, ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace 2015;17:767–777.
11.Nichols, CI, Vose, JG. Incidence of bleeding-related complications during primary implantation and replacement of cardiac implantable electronic devices. J Am Heart Assoc 2017;6:pii: e004263.
12.Branch-Elliman, W, Stanislawski, M, Strymish, J, et al. Cardiac electrophysiology laboratories: a potential target for antimicrobial stewardship and quality improvement? Infect Control Hosp Epidemiol 2016;37:1005–1011.
13.Baddour, LM, Epstein, AE, Erickson, CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458–477.
14.Sandoe, JA, Barlow, G, Chambers, JB, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother 2015;70:325–359.
15.Nielsen, JC, Gerdes, JC, Varma, N. Infected cardiac-implantable electronic devices: prevention, diagnosis, and treatment. Eur Heart J 2015;36:2484–2490.
16.Epitools: Epidemiology Tools. R package version 0.5-92017 [computer program].
17.Elixhauser, A, Steiner, C, Harris, DR, Coffey, RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27.
18.R: A Language and Environment for Statistical Computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2017.
19.Asundi, A, Stanislawski, M, Mehta, P, et al. Prolonged antimicrobial prophylaxis following cardiac device procedures increases preventable harm: insights from the VA CART program. Infect Control Hosp Epidemiol 2018;39:1030–1036.
20.Chen, HC, Chen, MC, Chen, YL, et al. Bundled preparation of skin antisepsis decreases the risk of cardiac implantable electronic device-related infection. Europace 2016;18:858–867.
21.George, S, Leasure, AR, Horstmanshof, D. Effectiveness of decolonization with chlorhexidine and mupirocin in reducing surgical site infections: a systematic review. Dimen Crit Care Nurs 2016;35:204–222.
22.Lee, WH, Huang, TC, Lin, LJ, et al. Efficacy of postoperative prophylactic antibiotics in reducing permanent pacemaker infections. Clin Cardiol 2017;40:559–565.
23.Basil, A, Lubitz, SA, Noseworthy, PA, et al. Periprocedural antibiotic prophylaxis for cardiac implantable electrical device procedures: results from a Heart Rhythm Society survey. JACC Clin Electrophysiol 2017;3:632–634.
24.Bratzler, DW. Surgical care improvement project performance measures: good but not perfect. Clin Infect Dis 2013;56:428–429.
25.Harbarth, S, Samore, MH, Lichtenberg, D, Carmeli, Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000;101:2916–2921.
26.Rosenberger, LH, Politano, AD, Sawyer, RG. The surgical care improvement project and prevention of post-operative infection, including surgical site infection. Surg Infect (Larchmt) 2011;12:163–168.
27.Bratzler, DW, Houck, PM, Richards, C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg 2005;140:174–182.
28.Bratzler, DW, Dellinger, EP, Olsen, KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013;70:195–283.
29.Bolon, MK, Morlote, M, Weber, SG, et al. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis 2004;38:1357–1363.
30.Kang, FG, Liu, PJ, Liang, LY, et al. Effect of pocket irrigation with antimicrobial on prevention of pacemaker pocket infection: a meta-analysis. BMC Cardiovasc Disord 2017;17:256.
31.Lakshmanadoss, U, Nuanez, B, Kutinsky, I, et al. Incidence of pocket infection postcardiac device implantation using antibiotic versus saline solution for pocket irrigation. Pacing Clin Electrophysiol 2016;39:978–984.
32.Edin, ML, Miclau, T, Lester, GE, Lindsey, RW, Dahners, LE. Effect of cefazolin and vancomycin on osteoblasts in vitro. Clin Orthop Relat Res 1996:245–251.
33.Henrikson, CA, Sohail, MR, Acosta, H, et al. Antibacterial envelope is associated with low infection rates after implantable cardioverter-defibrillator and cardiac resynchronization therapy device replacement: results of the citadel and centurion studies. JACC Clin Electrophysiol 2017;3:1158–1167.
34.Koerber, SM, Turagam, MK, Winterfield, J, Gautam, S, Gold, MR. Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: a meta-analysis. J Cardio Electrophysiol 2018;29:609–615.
35.Tarakji, KG, Mittal, S, Kennergren, C, et al. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med 2019. doi: 10.1056/NEJMoa1901111. [Epub ahead of print].
36.Turagam, MK, Nagarajan, DV, Bartus, K, Makkar, A, Swarup, V. Use of a pocket compression device for the prevention and treatment of pocket hematoma after pacemaker and defibrillator implantation (STOP-HEMATOMA-I). J Intervent Cardiac Electrophysiol 2017;49:197–204.
37.Douketis, JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood 2011;117:5044–5049.
38.Pindyck, T, Gupta, K, Strymish, J, et al. Validation of an electronic tool for flagging surgical site infections based on clinical practice patterns for triaging surveillance: operational successes and barriers. Am J Infect Control 2018;46:186–190.